View Future GrowthCHO Pharma 過去の業績過去 基準チェック /06CHO Pharmaは0.6%の年平均成長率で業績を伸ばしているが、Pharmaceuticals業界はgrowingで9.4%毎年増加している。売上は成長しており、年平均16.8%の割合である。主要情報0.64%収益成長率4.23%EPS成長率Pharmaceuticals 業界の成長18.53%収益成長率16.75%株主資本利益率-11.77%ネット・マージン-20,265.97%前回の決算情報31 Dec 2025最近の業績更新Reported Earnings • Apr 26Full year 2025 earnings released: NT$1.36 loss per share (vs NT$0.99 loss in FY 2024)Full year 2025 results: NT$1.36 loss per share (further deteriorated from NT$0.99 loss in FY 2024). Net loss: NT$290.0m (loss widened 37% from FY 2024). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 27Full year 2020 earnings released: NT$1.62 loss per share (vs NT$1.96 loss in FY 2019)Full year 2020 results: Net loss: NT$296.8m (loss narrowed 17% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings.すべての更新を表示Recent updatesReported Earnings • Apr 26Full year 2025 earnings released: NT$1.36 loss per share (vs NT$0.99 loss in FY 2024)Full year 2025 results: NT$1.36 loss per share (further deteriorated from NT$0.99 loss in FY 2024). Net loss: NT$290.0m (loss widened 37% from FY 2024). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.お知らせ • Mar 27CHO Pharma, Inc., Annual General Meeting, Jun 25, 2026CHO Pharma, Inc., Annual General Meeting, Jun 25, 2026. Location: 2 floor building. c no,99 ln.130, sec.1 yen chiu yuan rd., nangang district, taipei city TaiwanNew Risk • Mar 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (NT$3.2m revenue, or US$101k). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (7.6% average weekly change).New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (NT$3.2m revenue, or US$102k). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).お知らせ • Mar 03CHO Pharma, Inc., Annual General Meeting, Jun 26, 2025CHO Pharma, Inc., Annual General Meeting, Jun 26, 2025.New Risk • Feb 24New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.5% average weekly change). Revenue is less than US$1m (NT$1.1m revenue, or US$33k). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).New Risk • Feb 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.2% average weekly change). Revenue is less than US$1m (NT$1.1m revenue, or US$33k).お知らせ • Mar 17CHO Pharma, Inc., Annual General Meeting, Jun 27, 2024CHO Pharma, Inc., Annual General Meeting, Jun 27, 2024.New Risk • Feb 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (NT$60k revenue, or US$1.9k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (16% increase in shares outstanding).New Risk • Nov 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (NT$60k revenue, or US$1.9k). Minor Risk Shareholders have been diluted in the past year (16% increase in shares outstanding).Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director & Member of Scientific Advisory Board Mei-Shang Ho was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Liu Shuan-Ta was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Mar 27Full year 2020 earnings released: NT$1.62 loss per share (vs NT$1.96 loss in FY 2019)Full year 2020 results: Net loss: NT$296.8m (loss narrowed 17% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings.分析記事 • Mar 24Here's Why We're Not Too Worried About CHO Pharma's (GTSM:6586) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although...Is New 90 Day High Low • Jan 06New 90-day low: NT$24.15The company is down 16% from its price of NT$28.80 on 08 October 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 14% over the same period.分析記事 • Dec 09We're Not Very Worried About CHO Pharma's (GTSM:6586) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Is New 90 Day High Low • Dec 09New 90-day low: NT$25.10The company is down 16% from its price of NT$30.00 on 10 September 2020. The Taiwanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 11% over the same period.Is New 90 Day High Low • Oct 22New 90-day low: NT$28.30The company is down 20% from its price of NT$35.35 on 24 July 2020. The Taiwanese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period.収支内訳CHO Pharma の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史TPEX:6586 収益、費用、利益 ( )TWD Millions日付収益収益G+A経費研究開発費31 Dec 251-2904028730 Sep 252-2603726130 Jun 253-2303523531 Mar 253-2213322731 Dec 244-2123221930 Sep 242-2343220930 Jun 241-2553319931 Mar 241-2813121931 Dec 230-3063023930 Sep 230-3172727730 Jun 230-3272431531 Mar 230-3332432131 Dec 220-3382532630 Sep 222-2982428430 Jun 224-2572324231 Mar 224-2322221831 Dec 214-2062019430 Sep 212-2232121230 Jun 210-2402123031 Mar 210-2692125931 Dec 200-2972228830 Sep 200-3282331730 Jun 200-3592434731 Mar 200-3592434631 Dec 190-3582534530 Sep 190-3472433530 Jun 190-3372332531 Mar 190-3222331131 Dec 180-3072229730 Sep 180-3092729530 Jun 180-3123229431 Mar 180-3103429131 Dec 170-3093528930 Sep 171-2933227630 Jun 171-2783026431 Mar 171-2622525431 Dec 162-2452124330 Sep 161-2031421130 Jun 161-161717831 Mar 160-1353160質の高い収益: 6586は現在利益が出ていません。利益率の向上: 6586は現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 6586は利益を出していないが、過去 5 年間で年間0.6%の割合で損失を削減してきた。成長の加速: 6586の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: 6586は利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -5% ) と比較することは困難です。株主資本利益率高いROE: 6586は現在利益が出ていないため、自己資本利益率 ( -11.77% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/12 17:45終値2026/08/12 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋CHO Pharma, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Apr 26Full year 2025 earnings released: NT$1.36 loss per share (vs NT$0.99 loss in FY 2024)Full year 2025 results: NT$1.36 loss per share (further deteriorated from NT$0.99 loss in FY 2024). Net loss: NT$290.0m (loss widened 37% from FY 2024). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 27Full year 2020 earnings released: NT$1.62 loss per share (vs NT$1.96 loss in FY 2019)Full year 2020 results: Net loss: NT$296.8m (loss narrowed 17% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Apr 26Full year 2025 earnings released: NT$1.36 loss per share (vs NT$0.99 loss in FY 2024)Full year 2025 results: NT$1.36 loss per share (further deteriorated from NT$0.99 loss in FY 2024). Net loss: NT$290.0m (loss widened 37% from FY 2024). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
お知らせ • Mar 27CHO Pharma, Inc., Annual General Meeting, Jun 25, 2026CHO Pharma, Inc., Annual General Meeting, Jun 25, 2026. Location: 2 floor building. c no,99 ln.130, sec.1 yen chiu yuan rd., nangang district, taipei city Taiwan
New Risk • Mar 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (NT$3.2m revenue, or US$101k). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (7.6% average weekly change).
New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (NT$3.2m revenue, or US$102k). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).
お知らせ • Mar 03CHO Pharma, Inc., Annual General Meeting, Jun 26, 2025CHO Pharma, Inc., Annual General Meeting, Jun 26, 2025.
New Risk • Feb 24New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.5% average weekly change). Revenue is less than US$1m (NT$1.1m revenue, or US$33k). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).
New Risk • Feb 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.2% average weekly change). Revenue is less than US$1m (NT$1.1m revenue, or US$33k).
お知らせ • Mar 17CHO Pharma, Inc., Annual General Meeting, Jun 27, 2024CHO Pharma, Inc., Annual General Meeting, Jun 27, 2024.
New Risk • Feb 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (NT$60k revenue, or US$1.9k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (16% increase in shares outstanding).
New Risk • Nov 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (NT$60k revenue, or US$1.9k). Minor Risk Shareholders have been diluted in the past year (16% increase in shares outstanding).
Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director & Member of Scientific Advisory Board Mei-Shang Ho was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Liu Shuan-Ta was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Mar 27Full year 2020 earnings released: NT$1.62 loss per share (vs NT$1.96 loss in FY 2019)Full year 2020 results: Net loss: NT$296.8m (loss narrowed 17% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings.
分析記事 • Mar 24Here's Why We're Not Too Worried About CHO Pharma's (GTSM:6586) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although...
Is New 90 Day High Low • Jan 06New 90-day low: NT$24.15The company is down 16% from its price of NT$28.80 on 08 October 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 14% over the same period.
分析記事 • Dec 09We're Not Very Worried About CHO Pharma's (GTSM:6586) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Is New 90 Day High Low • Dec 09New 90-day low: NT$25.10The company is down 16% from its price of NT$30.00 on 10 September 2020. The Taiwanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 11% over the same period.
Is New 90 Day High Low • Oct 22New 90-day low: NT$28.30The company is down 20% from its price of NT$35.35 on 24 July 2020. The Taiwanese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period.